ChemoCentryx climbs on expanded Vifor alliance

23 December 2016

Iron specialist Vifor Pharma, a company of the Swiss Galenica group (SIX: GALN), is to pay USA-based biopharma company ChemoCentryx (Nasdaq: CCXI) $50 million upfront in an expansion of a collaboration which will give it rights to renal diseases drug CCX140 outside the USA and China.

CCX140 is an orally-administered inhibitor of the chemokine receptor known as CCR2 and has previously completed a successful Phase II clinical trial in patients with diabetic kidney disease.

"CCX140 is a highly innovative approach, which is implicated in a number of kidney diseases, including diabetic nephropathy"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK